Rituximab plus chemotherapy in follicular and mantle cell lymphomas.

abstract：:The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the use of tamoxifen for the prevention of breast cancer, and the dramatic improvement in survival demonstrated with the use of the ...

journal_title：Seminars in oncology

authors： Wickerham DL,O'Connell MJ,Costantino JP,Cronin WM,Paik S,Geyer CE Jr,Ganz PA,Petrelli N,Mamounas EP,Julian TB,Wolmark N

更新日期：2008-10-01 00:00:00

abstract：:Relapse following complete remission achieved with a single course of high-dose chemotherapy continues to be the main cause of treatment failure in patients with metastatic breast cancer. A phase I/II trial was initiated that combined the two most active drugs against breast cancer, doxorubicin and paclitaxel (Taxol; ...

journal_title：Seminars in oncology

authors： Rahman Z,Champlin R,Rondon G,Frye D,Valero V,Mehra R,Hortobagyi G

更新日期：1997-10-01 00:00:00

abstract：:The humanized anti-p185(HER2) monoclonal antibody trastuzumab has been shown to effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The treatment of cancer cells with trastuzumab results in downregulation of the HER2 receptor. Further downstream cellular events include the a...

journal_title：Seminars in oncology

authors： Baselga J,Albanell J,Molina MA,Arribas J

更新日期：2001-10-01 00:00:00

abstract：:Distant metastasis is the major cause for therapeutic failures in Clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease....

journal_title：Seminars in oncology

authors： Gilboa E

更新日期：1996-02-01 00:00:00

abstract：:Colorectal cancer is an ideal model in which to study malignant progression from the molecular-genetic perspective because different stages of the same malignancy coexist within each patient. Approximately 75% of colorectal cancer cases are sporadic and the remaining are familial disease, yet genetic mutations that ha...

journal_title：Seminars in oncology

authors： Kitisin K,Mishra L

更新日期：2006-12-01 00:00:00

abstract：:For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer. It provided a response rate of 15% to 20%, with a median survival of approximately 1 year. In the past 5 years, remarkable progress has been made in colorectal cancer research with the approval of irinotecan ...

journal_title：Seminars in oncology

authors： Varadhachary GR,Hoff PM

更新日期：2005-12-01 00:00:00

abstract：:The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7-week total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combined with standard curative radiotherapy (RT) for pre...

journal_title：Seminars in oncology

authors： Rosenthal DI,Sinard RJ,Okani O,Corak J,Kavanaugh D,Kamen B,Vuitch FM,Gazdar AF,Griener J,Frenkel EP,Carbone DP

更新日期：1997-12-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, usually develops in a liver already suffering from chronic damages, often cirrhosis. There has been marked progress in the treatment of HCC. However, effective treatments are limited to patients with less advanced HCC. The detection of HCC at an...

journal_title：Seminars in oncology

authors： Masuzaki R,Karp SJ,Omata M

更新日期：2012-08-01 00:00:00

abstract：:Targeted therapy for breast cancer has existed since 1986, when Beatson published his observations on oophorectomy. In the past 5 years monoclonal antibodies and tyrosine kinase inhibitors have been evaluated in phase I and II clinical trials of breast cancer. Trastuzumab (Herceptin; Genentech, Inc, South San Francisc...

journal_title：Seminars in oncology

authors： Kaklamani V,O'Regan RM

更新日期：2004-04-01 00:00:00

abstract：:Myeloid neoplasms are characterized by acquired somatic mutations and epigenetic alterations in genes that are crucial for hematopoietic differentiation and cellular proliferation and survival pathways. The heterogeneity and genetic complexity of these disorders is daunting, but the improvement in our knowledge of the...

journal_title：Seminars in oncology

authors： Odenike O,Thirman MJ,Artz AS,Godley LA,Larson RA,Stock W

更新日期：2011-04-01 00:00:00

abstract：:Follicular lymphoma is a low-grade, indolent non-Hodgkin's lymphoma characterized by the presence of the t(14;18) translocation. The detection of this translocation using polymerase chain reaction techniques has been increasingly studied. However, the diagnostic and prognostic value of detecting t(14;18) rearrangement...

journal_title：Seminars in oncology

authors： Bordeleau L,Berinstein NL

更新日期：2000-12-01 00:00:00

abstract：:The sequencing of targeted therapy is well established in metastatic renal cancer. Switching between different vascular endothelial growth factor (VEGF)-targeted therapies or VEGF-targeted therapies and mammalian target of rapamycin (mTOR) inhibitors are both of proven benefit. The optimal sequence remains unclear. Un...

journal_title：Seminars in oncology

authors： Escudier B,Gore M

更新日期：2013-08-01 00:00:00

abstract：:Transport of folates and antifolates in most cells is mediated by the reduced folate carrier (RFCI), an anion exchanging concentrative process, which is opposed by independent exit pump(s) that are directly coupled to energy metabolism. The balance of these processes governs the free intracellular folate level that is...

journal_title：Seminars in oncology

authors： Sierra EE,Goldman ID

更新日期：1999-04-01 00:00:00

abstract：:The development of targeted agents has brought new opportunities and extraordinary therapeutic challenges to cancer therapy. Several agents that inhibit epidermal growth factor receptor (HER1/EGFR) tyrosine kinase have been developed and are advanced in their clinical development. Preclinical and clinical data show th...

journal_title：Seminars in oncology

authors： Hortobagyi GN,Sauter G

更新日期：2003-06-01 00:00:00

abstract：:For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active...

journal_title：Seminars in oncology

authors： Robert NJ,Vogel CL,Henderson IC,Sparano JA,Moore MR,Silverman P,Overmoyer BA,Shapiro CL,Park JW,Colbern GT,Winer EP,Gabizon AA

更新日期：2004-12-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) represents almost three quarters of all cases of lung cancer. Most NSCLC patients present with either locally advanced inoperable disease, stage IV metastatic disease, or comorbid medical conditions that make them unsuitable for curative resection. Among NSCLC patients in the United ...

journal_title：Seminars in oncology

authors： Carney DN

更新日期：1995-08-01 00:00:00

abstract：:Session IV of the Second International Colloquium on Cardio-Oncology held in Kraków, focused on the cardiovascular risks of using hormone replacement therapy in breast cancer and androgen deprivation therapy in prostate cancer and continued the theme from Session 3 with a discussion of risk reduction strategies. The d...

journal_title：Seminars in oncology

authors： Plummer C,Steingart RM,Jurczak W,Iakobishvili Z,Lyon AR,Plastaras JP,Minotti G

更新日期：2019-12-01 00:00:00

abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

journal_title：Seminars in oncology

authors： Cella D

更新日期：2004-12-01 00:00:00

abstract：:Successful allogeneic hematopoietic stem cell transplantation (HSCT) and solid organ transplantation require development of a degree of immune tolerance against allogeneic antigens. T lymphocytes play a critical role in allograft rejection, graft failure, and graft-versus-host disease (GVHD). T-cell tolerance occurs b...

journal_title：Seminars in oncology

authors： Alpdogan O,van den Brink MR

更新日期：2012-12-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) characterized by a specific genetic alteration, affecting the retinoic acid receptor-alpha (RARalpha), and leading to a blockage in the differentiation of the granulocytic cells. The accumulation of the promyelocytic blasts in the...

journal_title：Seminars in oncology

authors： Lo-Coco F,Ammatuna E,Montesinos P,Sanz MA

更新日期：2008-08-01 00:00:00

abstract：:Recent advances in understanding tumor-specific immunity have introduced new excitement in the clinical development of vaccines for the treatment of cancer. A better understanding of basic immunologic principles has led to a variety of techniques for enhancing tumor-specific immunity through vaccination. Approaches to...

journal_title：Seminars in oncology

authors： Arlen PM,Kaufman HL,DiPaola RS

更新日期：2005-12-01 00:00:00

abstract：:In this study, it has been shown that in 21 patients with AML the dCyd kinase and dCyd deaminase activities correspond closely to the clinical response to ara-C remission induction therapy. Patients with primary disease were treated with a conventional-dose ara-C regimen whereas nonresponders and relapsed patients fol...

journal_title：Seminars in oncology

authors： Colly LP,Peters WG,Richel D,Arentsen-Honders MW,Starrenburg CW,Willemze R

更新日期：1987-06-01 00:00:00

abstract：:Since its introduction, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antitumor activity in epidermoid carcinomas and adenocarcinomas originating in the esophagus. Paclitaxel is the most active single agent available to treat metastatic esophageal cancer. Combinations of ...

journal_title：Seminars in oncology

authors： Weiner LM

更新日期：1999-02-01 00:00:00

abstract：:Current data indicate that most elderly patients with acute myelogenous leukemia should be treated with intensive chemotherapy. Most should receive remission induction chemotherapy using cytarabine 100 to 200 mg/m2/d by constant intravenous infusion for five to seven days plus daunorubicin greater than or equal to 30 ...

journal_title：Seminars in oncology

authors： Champlin RE,Gajewski JL,Golde DW

更新日期：1989-02-01 00:00:00

abstract：:Breast cancer patients undergoing therapeutic regimens of high-dose chemotherapy (HDCT) with circulating progenitor cell support often develop anemia. As a general consideration in the transplantation setting, red blood cell transfusions are normally required in patients who have passed the myeloablative phase after H...

journal_title：Seminars in oncology

authors： Danova M,Ferrari S

更新日期：2002-06-01 00:00:00

abstract：:Letrozole has proven efficacious in a variety of therapeutic scenarios, including that of extended adjuvant therapy following 5 years of tamoxifen treatment in postmenopausal women with estrogen-receptor-positive early breast cancer. The Breast International Group 1-98 trial (BIG 1-98) is the first to study the effica...

journal_title：Seminars in oncology

authors： Forbes JF

更新日期：2006-04-01 00:00:00

abstract：:Although bone and soft tissue sarcomas are not common, a significant number of patients who develop these tumors will die with metastatic disease. Part of the reason is that many of the patients have advanced disease at diagnosis. Identification of an etiologic agent should allow for diagnosis at an earlier stage. Thi...

journal_title：Seminars in oncology

authors： McClay EF

更新日期：1989-08-01 00:00:00

abstract：:The combination of paclitaxel and carboplatin is now established as the standard first-line chemotherapy regimen for advanced ovarian cancer. Ways in which this standard therapy can be further improved are being investigated, and several approaches have been taken. One approach is to integrate a different cytotoxic ag...

journal_title：Seminars in oncology

authors： Thigpen T

更新日期：2006-04-01 00:00:00

abstract：:Elderly patients with malignant gliomas present unique treatment challenges. Data are limited on the efficacy of various treatment modalities for high-grade gliomas in the elderly patient population, particularly for patients over 70 years of age, and the most appropriate treatment strategies remain a matter of debate...

journal_title：Seminars in oncology

authors： Chinot OL

更新日期：2003-12-01 00:00:00

abstract：:Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passiv...

journal_title：Seminars in oncology

authors： Hwang LC,Fein S,Levitsky H,Nelson WG

更新日期：1999-04-01 00:00:00